help button home button Am J Pathol Epitomics, Inc.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Related articles in Am J Pathol
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Savinainen, K. J.
Right arrow Articles by Visakorpi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Savinainen, K. J.
Right arrow Articles by Visakorpi, T.
(American Journal of Pathology. 2002;160:339-345.)
© 2002 American Society for Investigative Pathology

Regular Articles

Expression and Gene Copy Number Analysis of ERBB2 Oncogene in Prostate Cancer

Kimmo J. Savinainen*, Outi R. Saramäki*, Marika J. Linja*, Ola Bratt{dagger}, Teuvo L. J. Tammela{ddagger}, Jorma J. Isola* and Tapio Visakorpi*

From the Laboratory of Cancer Genetics,*
Institute of Medical Technology, and the Department of Urology,{ddagger}
Tampere University Hospital, University of Tampere, Tampere, Finland; and the Unit of Urology,{dagger}
Helsingborg Hospital, Helsingborg, Sweden

An anti-ERBB2 antibody, trastuzumab, has been shown to be highly efficient in the treatment of metastatic breast cancers overexpressing the ERBB2 gene. It has been suggested that overexpression and even amplification of ERBB2 may play a role in the development of prostate cancer. Here, we have analyzed gene copy number and expression of the ERBB2 gene in both androgen-dependent primary and metastatic tumors, as well as recurrent hormone-refractory tumors. The expression levels were compared to the expression of ERBB2 in breast cancers with or without ERBB2 gene amplification. Of 126 prostate tumors, chromogenic in situ hybridization (CISH) revealed only 1 case containing borderline (six to eight copies) amplifications of ERBB2. This hormone-refractory tumor, however, did not express ERBB2 protein. Immunohistochemical staining of ERBB2 protein was negative (0 or 1+ intensity) in all prostate samples (n = 124) analyzed. To quantitate the level of ERBB2 mRNA expression in prostate tumors (n = 34) and cell lines (n = 3), as well as in breast tumors (n = 30) and cell lines (n = 16), real-time reverse transcriptase-polymerase chain reaction (LightCycler) methodology was used. The expression level was similar in all prostate tumor types and corresponded to the level of expression in breast carcinomas without ERBB2 amplification. Breast tumors with ERBB2 amplification expressed, on average, ~20 times (P < 0.001) higher mRNA levels than prostate tumors or breast carcinomas without the gene amplification. In conclusion, the expression of ERBB2 in prostate cancer is relatively low, and is not altered during disease progression. Thus, it is unlikely that treatment modalities relying on the overexpression of ERBB2 gene will be useful in treating prostate cancer.


Related articles in Am J Pathol:

This Month in AJP

Am J Pathol 2002 160: 1-2. [Full Text]  



This article has been cited by other articles:


Home page
 Cancer Res.Home page
M. Puhr, F. R. Santer, H. Neuwirt, M. Susani, J. A. Nemeth, A. Hobisch, L. Kenner, and Z. Culig
Down-regulation of Suppressor of Cytokine Signaling-3 Causes Prostate Cancer Cell Death through Activation of the Extrinsic and Intrinsic Apoptosis Pathways
Cancer Res., September 15, 2009; 69(18): 7375 - 7384.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Cai, D. C. Portnoy, H. Wang, X. Jiang, S. Chen, and S. P. Balk
Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2
Cancer Res., June 15, 2009; 69(12): 5202 - 5209.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
H. Neuwirt, M. Puhr, F. R. Santer, M. Susani, W. Doppler, G. Marcias, V. Rauch, M. Brugger, A. Hobisch, L. Kenner, et al.
Suppressor of Cytokine Signaling (SOCS)-1 Is Expressed in Human Prostate Cancer and Exerts Growth-Inhibitory Function through Down-Regulation of Cyclins and Cyclin-Dependent Kinases
Am. J. Pathol., May 1, 2009; 174(5): 1921 - 1930.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
H. Neuwirt, M. Puhr, I. T Cavarretta, M. Mitterberger, A. Hobisch, and Z. Culig
Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion
Endocr. Relat. Cancer, December 1, 2007; 14(4): 1007 - 1019.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Murphy, C. A. Hughes, C. Barrett, H. Magee, B. Loftus, J. J. O'Leary, and O. Sheils
Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2 Duplication, Androgen Resistance, and Decreased Survival
Cancer Res., March 15, 2007; 67(6): 2893 - 2898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. de Bono, J. Bellmunt, G. Attard, J. P. Droz, K. Miller, A. Flechon, C. Sternberg, C. Parker, G. Zugmaier, V. Hersberger-Gimenez, et al.
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
J. Clin. Oncol., January 20, 2007; 25(3): 257 - 262.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Bellezza, H. Neuwirt, C. Nemes, I. T. Cavarretta, M. Puhr, H. Steiner, A. Minelli, G. Bartsch, F. Offner, A. Hobisch, et al.
Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer
Am. J. Pathol., December 1, 2006; 169(6): 2199 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
G. Xinarianos, F. E. McRonald, J. M. Risk, N. L. Bowers, G. Nikolaidis, J. K. Field, and T. Liloglou
Frequent genetic and epigenetic abnormalities contribute to the deregulation of cytoglobin in non-small cell lung cancer
Hum. Mol. Genet., July 1, 2006; 15(13): 2038 - 2044.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
F. E. McRonald, T. Liloglou, G. Xinarianos, L. Hill, L. Rowbottom, J. E. Langan, A. Ellis, J. M. Shaw, J. K. Field, and J. M. Risk
Down-regulation of the cytoglobin gene, located on 17q25, in tylosis with oesophageal cancer (TOC): evidence for trans-allele repression
Hum. Mol. Genet., April 15, 2006; 15(8): 1271 - 1277.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
H Awaya, Y Takeshima, O Furonaka, N Kohno, and K Inai
Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung
J. Clin. Pathol., October 1, 2005; 58(10): 1076 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
C Hughes, A Murphy, C Martin, O Sheils, and J O'Leary
Molecular pathology of prostate cancer
J. Clin. Pathol., July 1, 2005; 58(7): 673 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. W. Gregory, Y. E. Whang, W. McCall, X. Fei, Y. Liu, L. A. Ponguta, F. S. French, E. M. Wilson, and H. S. Earp III
Heregulin-Induced Activation of HER2 and HER3 Increases Androgen Receptor Transactivation and CWR-R1 Human Recurrent Prostate Cancer Cell Growth
Clin. Cancer Res., March 1, 2005; 11(5): 1704 - 1712.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
R. Foley, D. Hollywood, and M. Lawler
Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease
Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by the American Society for Investigative Pathology.